/
PEPG
$1.78+$0.08 (+4.71%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$117.6M
69M shares
52-week range
$1.01 – $7.80
11% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.56%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-11.11
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $106.0K | $0 | $0 | $0 | $1.2M | $1.5M | $1.4M |
| Gross profit | −$106.0K | $0 | $0 | $0 | −$1.2M | −$1.5M | −$1.4M |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $620.0K | $1.1M | $23.8M | $54.1M | $68.1M | $76.5M | $71.0M |
| Operating income | −$1.4M | −$1.9M | −$27.1M | −$68.3M | −$84.8M | −$97.7M | −$93.6M |
| EBITDA | −$1.2M | −$1.8M | −$27.1M | −$64.9M | −$77.4M | −$89.1M | −$88.2M |
| Net income | −$1.3M | −$1.9M | −$27.3M | −$69.1M | −$78.6M | −$90.0M | −$89.7M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -0.06 | -0.18 | -1.22 | -4.42 | -3.30 | -2.85 | -2.12 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $37M | $-1.11 | $-1.38–$-0.89 | 6 |
| 2027 | $5M | $-1.19 | $-1.81–$-0.75 | 6 |
| 2028 | $31M | $-1.06 | $-1.69–$-0.79 | 5 |
| 2029 | $33M | $-0.89 | $-0.89–$-0.89 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.01
Price
$1.78
Implied downside
-43%
Peer comparison
PepGen Inc. Common Stock
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
www.pepgen.com- Employees
- 59
- IPO / List date
- May 6, 2022
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds PEPG.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 56,800 | $100.5K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PEPG yet.
